Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TYRA Stock Price Chart Interactive Chart >
TYRA Price/Volume Stats
| Current price | $16.07 | 52-week high | $16.86 |
| Prev. close | $15.70 | 52-week low | $4.93 |
| Day low | $15.73 | Volume | 28,100 |
| Day high | $16.86 | Avg. volume | 54,582 |
| 50-day MA | $12.95 | Dividend yield | N/A |
| 200-day MA | $9.20 | Market Cap | 681.95M |
Tyra Biosciences, Inc. (TYRA) Company Bio
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest TYRA News From Around the Web
Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.
Tyra Biosciences to Participate in Upcoming Investor ConferencesTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences: |
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and HighlightsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter and year ended December 31, 2022, and highlighted recent corporate progress. |
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into AchondroplasiaTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Imagine Institute in Paris, France. Achondroplasia, the most common form of dwarfism, is a sk |
TYRA Price Returns
| 1-mo | 25.84% |
| 3-mo | 111.45% |
| 6-mo | 82.82% |
| 1-year | 50.19% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 111.45% |
| 2022 | -45.98% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...